CClinicalTrials.gg
TerminatedNCT01579643LALAKUpdated Apr 17, 2018

OCT-guided LALAK in Children

An interventional study of OCT guided laser-assisted lamellar anterior keratoplasty (LALAK) and Penetrating Keratoplasty (KP) in Corneal Opacity, sponsored by Oregon Health and Science University. Terminated at 1 site in United States. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2018-04-17.

Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
1 Month to 18 Years
Sex
All
01

Study summary

The primary goal of the trial is to determine if laser-assisted lamellar anterior keratoplasty (LALAK) will reduce the risks of post-operative complications such as adhesions, glaucoma and cataract that are associated with pediatric penetrating keratoplasty (PK).

Read the detailed description

There is a great need for lamellar keratectomy in the treatment of congenital opacities because the rejection rate in pediatric PK is 4-5 times higher than in adults. In addition, the intraocular inflammatory reaction in infants often leads to synechiae, glaucoma, and cataract. Because LALAK does not penetrate the eye and preserves the host endothelium, it could reduce the risk of these complications. Keratoplasty must be performed at this early age to prevent amblyopia.

In this study, OCT-guided LALAK will be performed in patients whose vision is limited by opacity in the anterior 2/3 of the cornea. The objective is to determine if LALAK will provide an equal or better visual outcome than traditional PK without the associated post-operative complications.

02

Conditions studied

  • Corneal Opacity

Browse trials for

Keywords

  • cornea
  • opacity
  • congenital
03

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Vision limited by opacity in the anterior 2/3 of the corneal stroma
  • Posterior opacity and endothelial defect must be less than 1 mm in diameter

Exclusion criteria

Exclusion Criteria:

  • Presence of cataract
  • Presence of adhesions of the iris or lens to the cornea
  • Inability/unwillingness of parents to give informed consent
  • Inability of parents to commit to required visits to complete the study
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    LALAK

    Procedure: OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)

  • Active comparator
    Penetrating Keratoplasty (KP)

    Procedure: Penetrating Keratoplasty (KP)

Interventions

  • ProcedureOCT guided laser-assisted lamellar anterior keratoplasty (LALAK)

    1. The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth. 2. The host cornea bed will be prepared with an excimer laser. 3. Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed.

  • ProcedurePenetrating Keratoplasty (KP)

    1. A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea. 2. The donor cornea is then sutured where the patient's cornea was.

05

What researchers measure

Primary outcomes

  1. Number of LALAK patients with post operative complications compared to PK patients

    Results of PK and LALAK will be compared in terms of corneal clarity, graft rejection, intraocular pressure, and vision (if measurable).

    Time frame: 24 months

06

Study locations

1 site
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
07

Registry details

Key details

Study ID
NCT01579643
Lead sponsor
Oregon Health and Science University
Collaborators
National Institutes of Health (NIH), National Eye Institute (NEI)
Responsible party
David Huang (Bibiana Jin Reiser, MD: Assistant Professor of Clinical Ophthalmology, Children's Hospital Los Angeles) — Principal investigator
First posted
Apr 18, 2012
Start date
Jan 2012
Primary completion
Aug 31, 2016
Completion
Aug 31, 2016
Last update
Apr 17, 2018

Study contacts

Bibiana Reiser, MD
principal investigator · Children's Hospital Los Angeles

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion